Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

President Donald Trump says he’ll sign an executive order on Monday intended to lower the cost of drugs in the U.S.

That study established the company’s Astellas-partnered Nectin-4 ADC Padcev and Merck & Co.’s PD-1 king Keytruda as the ...

Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results , but sales fell by 1.6% year on year to $15.53 ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

Quarter ResultsFormycon reports strong operational performance and financial results for first quarter of 2025 12.05.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of this ...

Three Motley Fool contributors believe you can. Here's why they think Axsome Therapeutics (NASDAQ: AXSM), Iovance ...

The post shared by Ark’s multiomics analyst, Nemo M Despot, underscored that “AI is powering a self-reinforcing loop that ...

Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Col ...

President Donald Trump announced he will sign an executive order mandating that Americans pay no more for select prescription ...